HC Wainwright Issues Negative Estimate for RCUS Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for Arcus Biosciences in a research note issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.19) for the quarter, down from their previous estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q3 2025 earnings at ($1.24) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.04) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.30) EPS, FY2028 earnings at ($2.83) EPS and FY2029 earnings at ($1.63) EPS.

A number of other equities analysts have also recently issued reports on RCUS. Wells Fargo & Company lowered their target price on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Wedbush restated an "outperform" rating and set a $33.00 target price on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Morgan Stanley decreased their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Bank of America decreased their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Finally, The Goldman Sachs Group decreased their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.67.

Arcus Biosciences Trading Down 2.2%

Shares of NYSE RCUS traded down $0.19 during mid-day trading on Friday, hitting $8.48. The company's stock had a trading volume of 540,883 shares, compared to its average volume of 836,297. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences has a one year low of $6.50 and a one year high of $18.98. The company's fifty day simple moving average is $8.35 and its 200-day simple moving average is $12.28. The stock has a market cap of $897.90 million, a price-to-earnings ratio of -2.69 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business's quarterly revenue was down 80.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.05) EPS.

Insider Activity

In other Arcus Biosciences news, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, with a total value of $201,200.00. Following the purchase, the director now directly owns 28,400 shares of the company's stock, valued at approximately $285,704. This represents a 238.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78% increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Gilead Sciences Inc. boosted its stake in Arcus Biosciences by 4.5% in the first quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company's stock valued at $246,684,000 after acquiring an additional 1,363,636 shares in the last quarter. Vanguard Group Inc. grew its stake in Arcus Biosciences by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after acquiring an additional 1,298,584 shares during the period. Woodline Partners LP increased its stake in Arcus Biosciences by 1.3% during the 4th quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock worth $52,471,000 after buying an additional 45,497 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Arcus Biosciences by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after purchasing an additional 178,351 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in Arcus Biosciences during the fourth quarter worth about $23,857,000. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.